treatment of malignant tumors with antigen peptide-specific dc-ctl cells and decitabine

Conditions: Malignant Tumor

Summary: tumor-specific antigens can be induced by demethylation drugs. antigen-targeting dc-ctl cells supposed to eliminate cancer cells efficiently and specifically. in this study investigators co-culture dcs cells with peptides derived from tumor specific antigen to generate antigen-specific dc-ctls (ag-ctl). following treatment with demethylation drugs, ag-ctl will be used to eliminate tumor cells. this study aims to evaluate the effectiveness and safety of ag-ctl combined with demethylation drugs.

a large number of studies have confirmed that demethylated drug decitabine can effectively induce tumor-specific antigen expression. tumor-specific antigens have strong specificity and are ideal therapeutic targets. in this study, tumor-specific antigens were used as therapeutic targets. the researchers screened the tumor-specific epitope peptides through bioinformatics database combined with in vitro experiments. the peptide-loaded dcs are co-cultured with t lymphocytes to induce the proliferation of ctls, which are then refusion to tumor patients to treating diseases.

Eligibility criteria:
inclusion criteria: 1. male or female patients aged 18-70 (including 18 and 70 years old); 2. diagnosed as malignant tumor by pathological and histological examination; 3. patients with ecog score \ 3 months; 4. patients need to receive systemic combined chemotherapy according to their condition; other treatments such as surgery, radiotherapy, and targeted therapy are excluded; 5. the previous treatment-related toxicity of the patient 2 weeks before the enrollment had returned to \<1 grade at the time of enrollment (except for low-grade toxicity such as alopecia and peripheral neuritis); 6. the patient's intravenous access is unobstructed, which can meet the needs of intravenous drip; 7. the patient voluntarily participates and signs the informed consent form, and follows the research treatment plan and visit plan; exclusion criteria: * any one of the exclusion criteria shall not be included in the group: 1. patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones) 2. people with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. patients treated with other cellular immune products (dc, t, nk, and car-t, etc.); 4. the patient had uncontrollable infections within 4 weeks before enrollment; 5. active hbv dna\>1000copy/ml/c hepatitis (anti-hcv positive, hcv rna positive), hiv positive, syphilis positive; 6. the patient participated in other clinical studies within 6 weeks before enrollment; 7. patients suffering from mental illness; 8. the patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results; 9. the patient has alcohol dependence; 10. women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period; 11. according to the judgment of the investigator, the patient has other unsuitable conditions for enrollment.